After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Tarsus Pharmaceuticals Inc is $2.95B. A total of 0.82 million shares were traded on the day, compared to an average of 659.91K shares.
In the most recent transaction, Azamian Bobak R. sold 6,000 shares of TARS for 55.37 per share on Sep 24 ’25. After the transaction, the President/CEO and Board Chair now owns 812,106 company shares. In a previous transaction on Sep 24 ’25, Bobak Azamian Living Trust bought 6,000 shares at 55.37 per share.
Among the insiders who sold shares, LINK WILLIAM J PHD disposed of 27,116 shares on Sep 08 ’25 at a per-share price of $57.00. This resulted in the Director holding 143,332 shares of TARS after the transaction. In another insider transaction, LINK WILLIAM J PHD bought 27,116 shares at $57.01 per share on Sep 08 ’25.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, TARS has a high of $76.81 and a low of $38.51.
As of this writing, TARS has an earnings estimate of -$0.07 per share for the current quarter. EPS was calculated based on a consensus of 3.0 estimates, with a high estimate of -$0.01 per share and a lower estimate of -$0.17. The company reported an EPS of -$0.6 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. TARS’s latest balance sheet shows that the firm has $171.81M in Cash & Short Term Investments as of fiscal 2021. There were $1.89M in debt and $11.48M in liabilities at the time. Its Book Value Per Share was $7.88, while its Total Shareholder’s Equity was $166.73M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TARS is Buy with a score of 4.56.
